AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05993364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free Aspire with Expiratory Flow Accelerator (EFA) technology
Description: Treatment sessions during which the EFA technology is used. Depending on the patient's clinical conditions, an oxygen additional support can be provided, while using the device. If present, during the sessions the tracheal cannula must be cuffed. Tracheal cannula aspiration must be provided when necessary. Sessions take place three times a day and take 20 minutes each time, from Monday to Saturday.
Study NCT05993364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In-Exufflator Machine
Description: Sessions using the In-Exufflator machine to improve the cough function, when the oxygen saturation decreases and the bronchial secretions increases.
Study NCT05993364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Exufflator Machine
Description: Sessions using the In-Exufflator machine to improve the cough function, when the oxygen saturation decreases and the bronchial secretions increases.
Study NCT05993364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional respiratory treatment
Description: Standard rehabilitative treatment to improve the secretions management, that includes:~* A change of the patient posture every three hours;~* Airways humidification depending on the secretions features;~* Aspiration in the tracheal cannula whenever necessary.
Study NCT05993364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional respiratory treatment
Description: Standard rehabilitative treatment to improve the secretions management, that includes:~* A change of the patient posture every three hours;~* Airways humidification depending on the secretions features;~* Aspiration in the tracheal cannula whenever necessary.
Study NCT05993364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional swallowing treatment
Description: Traditional rehabilitative treatment carried out by the speech and language pathologist in order to:~* Obtain decannulation (when a tracheal cannula is applied) following the Bargellesi Protocol steps;~* Improve oral structures strength and motility;~* Improve oral and perioral sensitivity with thermal or gustative or tactile stimulations;~* Improve the swallowing function with food trials of different consistencies, volume and temperature;~* Improve swallow efficacy and safety through the prescription of compensatory postures;
Study NCT05993364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional swallowing treatment
Description: Traditional rehabilitative treatment carried out by the speech and language pathologist in order to:~* Obtain decannulation (when a tracheal cannula is applied) following the Bargellesi Protocol steps;~* Improve oral structures strength and motility;~* Improve oral and perioral sensitivity with thermal or gustative or tactile stimulations;~* Improve the swallowing function with food trials of different consistencies, volume and temperature;~* Improve swallow efficacy and safety through the prescription of compensatory postures;
Study NCT06580041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Sensitivity Therapy (MBSST)
Description: CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions.
Study NCT06580041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment (CGT)
Description: CAU plan modified to include a trial of CGT.
Study NCT06580041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual (CAU) plan
Description: Unmodified CAU plan.
Study NCT06475105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Acetazolamide
Description: Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
Study NCT06475105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
Study NCT06464484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG (ATCC 53103)
Description: Already mentioned in arm/group descriptions
Study NCT04815070 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasonic measurement of antral area
Description: Ultrasound exam is done before the induction of spinal anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~The cross-sectional area (CSA) of antrum is shown by the following formula: CSA = AP x CC x ㅠ/4.~Antral area will correspond to the average of the three measures.
Study NCT04711993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Patients will do aerobic exercise three days a week for 40 minutes during 8 weeks. Aerobic exercise protocol will consist of warm up, loading and cooling periods. . Exercise prescription will be prepared in line with the recommendations of The American College of Sports Medicine.
Study NCT04711993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretchin exercise
Description: Patients will do stretching exercise three days a week for 40 minutes during 8 weeks. Stretching exercises will start with active warm-up activities. Static stretching method will be used.
Study NCT06187129 — intervention group
Intervention type: DEVICE
Intervention: nerve ultrasound
Description: nerve ultrasound
Study NCT05143060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cereal powder
Description: Eat or drink oral glucose (reference) the valley of fiber powder upgrade formula, perfect meals, by extraction shu cereal bars, light appearance suits (by extraction shu compound dietary fiber powder, feeding combination 1:1) and 17 extraction enzyme 6 kinds of food respectively in different periods.
Study NCT05143060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pure glucose powder
Description: Pure glucose powder
Study NCT05910840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support-t
Description: Support-t plus usual diabetes care for 18 months
Study NCT04518449 — intervention group
Intervention type: PROCEDURE
Intervention: medial border along the left side of SMA
Description: to place the medial border along the left side of SMA in laparoscopic D3 lymphadenectomy for right colon cancer
Study NCT04518449 — intervention group
Intervention type: PROCEDURE
Intervention: medial border along the left side of SMV
Description: to place the medial border along the left side of SMV in laparoscopic D3 lymphadenectomy for right colon cancer
Study NCT05643859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Description: Given PO
Study NCT05643859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proctoscopy or anoscopy with Biopsy
Description: Undergo proctoscopy or anoscopy
Study NCT05643859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo Colonoscopy
Study NCT05643859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06273553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RG002 injection
Description: In Part A, there are three dose cohorts that are 25µg,75µg and 150µg. In Part B, there will 1 or 2 dose levels according to the results of Part A. All subjects will receive a total of three RG002 Injections, administered intramuscularly at assigned dose level, with a dosing frequency of every 2 weeks (D1, D15, and D29).
Study NCT05422248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Series Topical Oxygen Therapy
Description: Standard care provided to the whole wound followed by intervention device care to the whole wound.
Study NCT05422248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paired Topical Oxygen Therapy
Description: Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.
Study NCT05746546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine patch
Description: Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
Study NCT04617457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)
Description: preoperative chemotherapy
Study NCT05563454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840
Description: Administration of dosage form 1 under diet 1 condition
Study NCT05667090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral supplementaiton of 576,000 IU once a week of vitamin D3 for 4 weeks
Study NCT05667090 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral supplementaiton of placebo once a week for 4 weeks
Study NCT06467266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acute Haemodynamic Study
Description: Multisite temporary pacing
Study NCT05625477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 (low dose)
Description: Single dose of TNM002 administered by intramuscular injection
Study NCT05625477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 (medium dose)
Description: Single dose of TNM002 administered by intramuscular injection
Study NCT05625477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 (high dose)
Description: Single dose of TNM002 administered by intramuscular injection
Study NCT05625477 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HTIG
Description: Single dose of HTIG administered by intramuscular injection
Study NCT05625477 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo administered by intramuscular injection
Study NCT05580224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes. One of three electrodes is placed across the 4th or 5th portal vein branches near the target tumor which enables anatomical ablation of tumor.
Study NCT05637645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midline Approach
Description: In the midline approach, the spinal approach to the intrathecal space is midline with a straight line shot. After infiltration with lidocaine, the spinal needle is introduced into the skin, angled slightly cephalic. The needle traverses the skin, followed by subcutaneous fat. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
Study NCT05637645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paramedian Approach
Description: The paramedian approach involves inserting the spinal needle 1 cm away from the midline in medial direction. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
Study NCT05637645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Taylors approach
Description: his arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
Study NCT04717128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding Skills Workshop
Description: Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
Study NCT04717128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding Skills Workshop
Description: Participants will complete the standardized patient-led breastfeeding skills workshop where they will learn breast massage techniques to alleviate plugged ducts and engorgement, hand expression of breast milk, effective breast pump use, and newborn positioning and attachment.
Study NCT05525819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group
Description: The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
Study NCT05525819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal group
Description: The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
Study NCT05525819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous group
Description: The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
Study NCT05410652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of fecal samples with diagnostic kit
Description: The 23S rRNA mutation site of clarithromycin and gyrA mutation site of levofloxacin were detected by Helicobacter Pylori fecal Gene Mutation Detection Kit.
Study NCT05410652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sanger Sequencing group
Description: Detection of gyrA and 23S rRNA mutations in H. pylori isolated from Gastric Mucosa by Sanger Sequencing
Study NCT05410652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bacterial culture and drug sensitivity test of gastric mucosa samples
Description: First, a sample of the patient's gastric mucosa will be obtained through gastroscopy. Then, Helicobacter pylori culture and drug sensitivity test can be carried out. Finally, the resistance data of Helicobacter pylori to clarithromycin and levofloxacin will be obtained.
Study NCT04877262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight maintenance diet (WMD)
Description: A diet meeting the participant's weight maintenance energy needs will be provided.
Study NCT06380478 — intervention group
Intervention type: DEVICE
Intervention: aspicio Monofocal IOL
Description: A bi-aspheric monofocal IOL is implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
Study NCT05353192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Description: Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
Study NCT06263335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Intervention
Description: During an eight-week intervention period, clients were to engage in mindfulness practices lasting between 45 minutes to an hour each session. The intervention would incorporate various components of the Mindfulness-Based Stress Reduction (MBSR) program, including mindfulness of the present moment, body scans, mindful eating, walking meditation, yoga exercises, and discussions on applying mindfulness to everyday experiences and stress management. Sessions would typically range from 30 to 90 minutes per week, with an additional full-day retreat session towards the end of the program. In addition to mindfulness practice, participants were to receive teachings on stress management and its application to interpersonal and daily life situations.
Study NCT05041088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProdromeNeuro Plasmalogen
Description: The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among participants with age-related cognitive decline.
Study NCT04619823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection Mosquito collection at home
Study NCT05487209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI,SCC-Ag
Description: Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen
Study NCT06211816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: communication strategy
Description: an intensive communication strategy on end-of-life practice was implemented, based on a framework developed by the International Delphi Conference.
Study NCT06317701 — intervention group
Intervention type: DEVICE
Intervention: Hypoglossal Nerve Stimulation (HGNS)
Description: Alternative therapy for Obstructive Sleep Apnea
Study NCT06214429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vascular Ultrasound
Description: Complete vascular ultrasound routine in B mode, color mode and Doppler.
Study NCT06214429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Shear Wave Elastography
Description: Vascular ultrasound assisted shear wave elastography of the atherosclerotic plaque.
Study NCT06214429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Greyscale Median
Description: Vascular ultrasound assisted assessment of the plaque in B mode. The plaque image will be post-processed for the histogram median value for the plaque area.
Study NCT06214429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Assessment of the plaque and carotid residual lumen by magnetic resonance.
Study NCT06214429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology
Description: Histopathology findings for patients that undergo carotid endarterectomy.
Study NCT06382623 — intervention group
Intervention type: PROCEDURE
Intervention: The percutaneous A1 pulley release
Description: Ultrasound-guided percutaneous pulley release is a procedure aimed at loosening the pulley using various cutting instruments or hypodermic needles under ultrasound guidance.
Study NCT06382623 — intervention group
Intervention type: OTHER
Intervention: The peritendinous Betamethasone group
Description: USG-guided injection of corticosteroid between the A1 pulley and the flexor tendon sheath.
Study NCT05483010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin is commercially available.
Study NCT05483010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin is commercially available.
Study NCT04989049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid 5 MG
Description: folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
Study NCT04989049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive drug looking exactly like active drug will be given, patients will be asked to put it on ulcers 2 times per day
Study NCT05542173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BALI association
Description: BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
Study NCT05695157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture-TOOL
Description: Suture device for fast and standardized closure of the abdominal fascia
Study NCT06176833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Supported Treadmill Training
Description: For these training sessions, participants will undergo walking training sessions that consist of wearing a harness for either body weight support or as a safety precaution while walking on a treadmill.
Study NCT06021236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based intervention
Description: Diet meditation breath awareness body scan mindfulness yoga Compassionate blessing
Study NCT06021236 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CIED procedure routine care
Description: CIED procedure home care guidance
Study NCT06021236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIED procedure routine care
Description: CIED procedure home care guidance
Study NCT05542173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
Study NCT06262581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisleizumab(BGB-A317)
Description: 200mg i.v. q3w
Study NCT05690932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Tablet
Description: Single dose of PBI-200 tablet
Study NCT05690932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Capsule
Description: Single dose of PBI-200 capsule
Study NCT05690932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-200 Suspension
Description: Single dose of PBI-200 suspension
Study NCT06107569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (Promicrobioma)
Description: Fecal microbiota transplant with Promicrobioma (freeze-dried isolated microbiota)